The terms IUGR and SGA are often
used synonymously. The definition considers only the birth weight without any
consideration of the in-utero growth and physical characteristics at birth.
Small for gestational age (SGA) refers to an infant born with a birth weight less than the 10th centile.But severe SGA refers to an infant born with a birth weight less
than the 3rd centile.
Such foetus or neonates fall into three groups.
Type A:--Babies whose growth at all gestational ages has been low.
They are SGA but otherwise healthy. 50-70% of SGA fetuses are constitutionally small, with fetal growth
appropriate for maternal size and ethnicity.
·
Type B:-Growth is normal in the
early part of pregnancy but slows in utero by at least two measurements (normally
from ultrasound assessments). This is due to intrauterine
growth restriction (IUGR). The newborn baby has a wasted appearance with little
subcutaneous fat and a greater risk of complications.
·
Type
C:--Non-placenta mediated growth restriction
– e g, structural or chromosomal anomaly, inborn errors of metabolism or fetal
infection.
However, there is a difference in
meaning.
The SGA definition is based on the
cross-sectional evaluation (either prenatal or postnatal) and this term has
been used for those neonates whose birth weight is less
than the 10th percentile for that particular gestational age or two standard
deviations below the population norms on the growth charts.
·
IUGR is a clinical definition and applies to in-utero
growth restriction, and neonates born with clinical features of malnutrition
and irrespective of their birth weight percentile.
A baby may not be SGA but may still
be considered to have had IUGR if they have features of in-utero growth restriction
and malnutrition at the time of birth. Therefore, neonates with a birth weight less than the 10th percentile will be SGA but not an IUGR
if there are no features of malnutrition. A neonate with a birth weight
greater than the 10th percentile will be an IUGR, in spite of not being SGA, if
the infants have features of malnutrition at birth.
Risk factors of IUGR/
SGA:
A)
Maternal factors can affect placental transfer of nutrients - eg, low
pre-pregnancy weight, under-nutrition, substance abuse or severe anaemia. Medical conditions can affect
placental implantation and vasculature and hence transfer - eg, pre-eclampsia,
autoimmune disease, thrombophilias, renal disease, diabetes and essential
hypertension.
All women should be assessed at
booking for risk factors for an SGA fetus/neonate to identify those who require
increased surveillance. Risk assessment must always be individualised, taking
into account previous medical and obstetric history and current pregnancy
history.
Minor risk factors
·
Maternal age ≥35 years.
·
IVF singleton pregnancy.
·
Nulliparity.
·
BMI <20.
·
BMI 25-34.9.
·
Smoker - 1-10 cigarettes per day.
·
Low fruit intake pre-pregnancy.
·
Pregnancy interval <6 months.
·
Pregnancy interval ≥60 months.
Major risk factors
·
Maternal age >40 years.
·
Smoker - ≥11 cigarettes per day.
·
Paternal or maternal SGA.
·
Cocaine use.
·
Daily vigorous exercise.
·
Previous SGA baby.
·
Previous stillbirth.
·
Chronic hypertension.
·
Diabetes with vascular disease.
·
Renal impairment.
·
Antiphospholipid syndrome.
·
Heavy bleeding similar to menses.
·
Pregnancy associated plasma
protein-A (PAPP-A) <0.4 multiples of the median (MOM).
Fetal echogenic bowel has been shown
to be independently associated with an SGA neonate and fetal demise.
Diagnosis : Abdominal palpation has limited accuracy for the prediction
of an SGA neonate and thus should not be routinely performed in this context.
·
Serial measurement of symphysis
fundal height (SFH) is recommended at each antenatal appointment from 24 weeks
of pregnancy as this improves prediction of an SGA neonate.
·
SFH should be plotted on a
customised chart rather than a population-based chart as this may improve
prediction of an SGA neonate.
·
Women with a single SFH which plots
below the 10th centile or with serial measurements which demonstrate slow or
static growth by crossing centiles should be referred for ultrasound
measurement of fetal size.
·
Women in whom measurement of SFH is
inaccurate (for example, BMI >35, large fibroids, hydramnios) should be
referred for serial assessment of fetal size, using ultrasound.
Management of FGR
A review found that effective
interventions are available for reducing the occurrence of SGA fetuses and
preventing related perinatal mortality. Some interventions are effective in all
women, while others target specific comorbidities.
The most effective interventions to
prevent the SGA fetus were antiplatelet agents like aspirin before 16 weeks in women at risk of
pre-eclampsia, and progesterone therapy for prevention of preterm birth.
For the prevention of perinatal
mortality in high-risk women, antiplatelets and antenatal corticosteroids were
found to be effective interventions.
The following is an account of the
recommendations provided in
the Royal College of Obstetricians and Gynaecologists (RCOG) guideline.
Antenatal ::-The
frequency of screening and follow up should depend upon the associated risk
factor. Women who have a major risk factor
should be referred for serial ultrasound measurement of fetal size and for
assessment of well-being with umbilical
artery Doppler from 26-28 weeks of pregnancy.
·
Women who have three or more minor
risk factors should be referred for uterine artery Doppler at 20-24 weeks of gestation.
·
In high-risk populations, uterine artery Doppler
at 20-24 weeks of pregnancy has a moderate predictive value for a severely SGA
neonate.
·
In women with an abnormal uterine
artery Doppler at 20-24 weeks of pregnancy, subsequent normalisation of flow
velocity indices is still associated with an increased risk of an SGA neonate.
Therefore, repeating uterine artery Doppler is of limited value.
·
Women with an abnormal uterine
artery Doppler at 20-24 weeks (pulsatility index >95th centile) and/or notching should be referred
for serial ultrasound measurement of fetal size and for assessment of
well-being with umbilical artery Doppler commencing at 26-28 weeks of
pregnancy.
·
Women with a normal uterine artery Doppler do
not require serial measurements of fetal size and serial assessment of
well-being with umbilical artery Doppler unless they develop specific pregnancy
complications – e g, antepartum hemorrhage or hypertension. However, they
should be offered a scan for fetal size and umbilical artery Doppler during the
third trimester.
·
Serial ultrasound measurement of
fetal size and assessment of well-being with umbilical artery Doppler should be
offered in cases of fetal echogenic bowel.
Investigations that are indicated in
SGA fetuses
·
Offer referral for a detailed fetal
anatomical survey and uterine artery Doppler by a fetal medicine specialist if
severe SGA is identified at the 18- to 20-week scan.
·
Karyotyping should be offered in
severely SGA
fetuses with structural anomalies and in those detected before 23 weeks of
gestation, especially if uterine artery Doppler is normal.
·
Serological screening for congenital
cytomegalovirus (CMV) and toxoplasmosis infection should be offered in severely
SGA fetuses.
·
Royal
College of Obstetricians and Gynaecologists (RCOG) guideline.
·
Testing for syphilis and malaria
should be considered in high-risk populations.
·
Uterine artery Doppler has limited
accuracy to predict adverse outcome in SGA fetuses diagnosed during the third
trimester.
Interventions to be considered in
the preterm SGA fetus
·
Women with an SGA fetus between 24+0
and 35+6 weeks of gestation, where delivery is being considered, should receive a
single course of antenatal corticosteroids.
Optimal method and frequency of
fetal surveillance in SGA
·
In a high-risk population, the use
of umbilical artery Doppler has been shown to reduce perinatal morbidity and
mortality. Umbilical artery
Doppler should be the primary surveillance tool in the SGA fetus.
·
When umbilical artery Doppler flow
indices are normal it is reasonable to repeat surveillance every 14 days. More
frequent Doppler surveillance may be appropriate in a severely SGA fetus.
·
When umbilical artery Doppler flow
indices are abnormal (pulsatility or resistance index >+2 standard
deviations above the mean for gestational age) and delivery is not indicated,
repeat surveillance twice each week in fetuses with end-diastolic velocities
present and daily in fetuses with absent/reversed end-diastolic frequencies.
·
Cardiotocography (CTG) should not be
used as the only form of surveillance in SGA fetuses.
·
Interpretation of the CTG should be
based on short-term fetal heart rate variation from computerised analysis.
·
Ultrasound assessment of amniotic
fluid volume should not be used as the only form of surveillance in SGA
fetuses.
·
Interpretation of amniotic fluid
volume should be based on the single deepest vertical pocket.
·
Biophysical profile should not be
used for fetal surveillance in preterm SGA fetuses.
·
In the preterm SGA fetus, middle
cerebral artery (MCA) Doppler has limited accuracy to predict acidaemia and
adverse outcome and should not be used to time delivery.
·
In the term SGA fetus with normal
umbilical artery Doppler, an abnormal MCA Doppler (pulsatility index <5th
centile) has moderate predictive value for acidosis at birth and should be used
to time delivery.
·
Ductus venosus Doppler has moderate
predictive value for acidaemia and adverse outcome.
·
Ductus venosus Doppler should be
used for surveillance in the preterm SGA fetus with abnormal umbilical artery
Doppler and used to time delivery.
The optimal gestation to deliver the
SGA fetus
·
In the preterm SGA fetus with
umbilical artery absent or reversed end-diastolic velocity (AREDV) detected
prior to 32 weeks of gestation, delivery is recommended when DV Doppler becomes
abnormal or umbilical vein pulsations appear, provided the fetus is considered
viable and after completion of steroids. Even when venous Doppler is normal,
delivery is recommended by 32 weeks of gestation and should be considered
between 30-32 weeks of gestation.
·
If MCA Doppler is abnormal, delivery
should be recommended no later than 37 weeks of gestation.
·
In the SGA fetus detected after 32
weeks of gestation with an abnormal umbilical artery Doppler, delivery no later
than 37 weeks of gestation is recommended.
·
In the SGA fetus detected after 32
weeks of gestation with normal umbilical artery Doppler, a senior obstetrician
should be involved in determining the timing and mode of birth of these
pregnancies.
·
Delivery should be offered at 37
weeks of gestation.
How the SGA fetus should be
delivered
·
In the SGA fetus with umbilical
artery AREDV, delivery by caesarean section is recommended.
·
In the SGA fetus with normal
umbilical artery Doppler or with abnormal umbilical artery pulsatility index
but end-diastolic velocities present, induction of labour can be offered but
rates of emergency caesarean section are increased and continuous fetal heart
rate monitoring is recommended from the onset of uterine contractions.
·
Early admission is recommended in
women in spontaneous labour with an SGA fetus in order to instigate continuous
fetal heart rate monitoring.
·
Continuous electronic fetal
monitoring should be offered
·
There is currently no evidence to
support immediate delivery
·
·
Prognosis
The prognosis for SGA babies depends
on whether they are A) constitutionally small, B) are small because of IUGR, or
are C) SGA due to non–placenta mediated growth restriction (eg, structural or
chromosomal anomaly, inborn errors of metabolism or fetal infection).
Normal constitutionally SGA babies
usually have an excellent prognosis assuming there is no other health problem
and the prognosis for babies with non–placenta mediated growth restriction will
depend on the underlying condition.
IUGR babies are prone to
complications after birth, including perinatal asphyxia, meconium aspiration,
persistent pulmonary hypertension, hypothermia, hypoglycaemia, hyperglycaemia,
hypocalcaemia, polycythaemia, jaundice, feeding difficulties, feed intolerance,
necrotising enterocolitis, late-onset sepsis and pulmonary hemorrhage.
IUGR babies also have an increased
risk of neuro-behavioural abnormalities, poor growth and increased susceptibility to adult-onset
diseases in infancy and adolescence, including obesity, metabolic syndrome,
type 2 diabetes and cardiovascular disease.
No comments:
Post a Comment